
Participants: n = 221
Excluded for criteria:
n = 14
Enrolled subjects: n = 207
Discontinuation of sitagliptin: n = 7
Failed data acquisition: n = 12
3 months
Subjects evaluated for efficacy：n = 188
12 months
Evaluation of the safety of sitagliptin